MiMedx Group (MDXG) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$355.2M

Revenue (quarter)

$64.4M

Revenue growth (year over year)

−34.73%

Gross profit (trailing twelve months)

$280.1M

Gross margin

78.85%

Net income (trailing twelve months)

$6.2M

Net income (quarter)

−$14.8M

Net income growth (year over year)

−254.29%

Net margin

1.76%

Return on equity

2.88%

EPS (trailing twelve months)

$0.05

Book value per share

$1.48

P/E (trailing twelve months)

109.47

Price to book

3.16

Debt to assets

23.13%

Payout ratio

—

Dividend yield

—

Company profile

MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.

• Is MiMedx Group (MDXG) profitable?

  Yes. MiMedx Group earned $6.2M in net income over the trailing twelve months, a net margin of 1.76%.

• How much revenue does MiMedx Group (MDXG) make?

  MiMedx Group generated $355.2M in revenue over the trailing twelve months, down 34.73% year over year.

• What is MDXG's P/E ratio?

  MiMedx Group trades at 109.5 times trailing twelve-month earnings, on an EPS of $0.05.

• How do I buy stock in MiMedx Group (MDXG)?

  MDXG trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.